OlympiAD final overall survival: Olaparib versus chemotherapy treatment of physician's choice (TPC) in patients with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm)

被引：3

作者：

Robson, Mark E. ^{[1
]}

Im, Seock-Ah ^{[2
]}

Senkus, Elzbieta ^{[3
]}

Xu, Binghe ^{[4
]}

Domchek, Susan ^{[5
]}

Masuda, Norikazu ^{[6
]}

Delaloge, Suzette ^{[7
]}

Li, Wei ^{[8
]}

Tung, Nadine ^{[9
]}

Armstrong, Anne ^{[10
]}

Wu, Wenting ^{[11
]}

Goessl, Carsten ^{[11
]}

Runswick, Sarah ^{[12
]}

Conte, Pierfranco ^{[13
,14
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[2] Seoul Natl Univ Hosp, Seoul, South Korea

[3] Med Univ Gdansk, Gdansk, Poland

[4] Chinese Acad Med Sci, Canc Hosp, Beijing, Peoples R China

[5] Univ Penn, Basser Ctr, Philadelphia, PA 19104 USA

[6] Natl Hosp Org, Osaka Natl Hosp, Osaka, Japan

[7] Inst Gustave Roussy, Villejuif, France

[8] Jilin Univ, Hosp 1, Changchun, Jilin, Peoples R China

[9] Dana Farber Harvard Canc Ctr, Beth Israel Deaconess Med Ctr, Boston, MA USA

[10] Christie Hosp NHS Fdn Trust, Manchester, Lancs, England

[11] AstraZeneca, Gaithersburg, MD USA

[12] AstraZeneca, Macclesfield, Cheshire, England

[13] Univ Padua, Padua, Italy

[14] Ist Oncol Veneto IRCCS, Padua, Italy

来源：

CANCER RESEARCH | 2018年 / 78卷 / 13期

关键词：

D O I：

10.1158/1538-7445.AM2018-CT038

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

CT038

引用

页数：2

共 50 条

[41] Efficacy of front-line treatment for hormone receptor-positive HER2-negative metastatic breast cancer with germline BRCA1/2 mutation [J].

Frenel, J. -S. ;

Lusque, A. ;

Delaloge, S. ;

Ferrero, J. -M. ;

Bachelot, T. ;

Desmoulins, I. ;

Levy, C. ;

Eymard, J. -C. ;

Goncalves, A. ;

Patsouris, A. ;

Reynier, M. A. Mouret ;

Thery, M. J. -C. ;

Petit, T. ;

Cabel, L. ;

Uwer, L. ;

Debled, M. ;

Chevrot, M. ;

Mailliez, A. ;

Jacot, W. ;

Rouge, T. de la Motte .

BRITISH JOURNAL OF CANCER, 2023, 128 (11) :2072-2080

[42] Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY [J].

Balmana, Judith ;

Fasching, Peter A. ;

Couch, Fergus J. ;

Delaloge, Suzette ;

Labidi-Galy, Intidhar ;

O'Shaughnessy, Joyce ;

Park, Yeon Hee ;

Eisen, Andrea F. ;

You, Benoit ;

Bourgeois, Hughes ;

Goncalves, Anthony ;

Kemp, Zoe ;

Swampillai, Angela ;

Jankowski, Tomasz ;

Sohn, Joo Hyuk ;

Poddubskaya, Elena ;

Mukhametshina, Guzel ;

Aksoy, Sercan ;

Timcheva, Constanta V. ;

Park-Simon, Tjoung-Won ;

Anton-Torres, Antonio ;

John, Ellie ;

Baria, Katherine ;

Gibson, Isabel ;

Gelmon, Karen A. ;

Koynova, Tatyana ;

Popov, Vasil ;

Timcheva, Constanta ;

Tomova, Antoaneta ;

Eisen, Andrea ;

Gelmon, Karen ;

Lemieux, Julie ;

Augereau, Paule ;

Bazan, Fernando ;

Becuwe, Celia ;

Bourgeois, Hugues ;

Chakiba, Camille ;

Chehimi, Mohamad ;

Cheneau, Caroline ;

Dalenc, Florence ;

de Guillebon, Eleonore ;

de la Motte Rouge, Thibault ;

Frenel, Jean-Sebastien ;

Goncalves, Anthony ;

Grenier, Julien ;

Hardy-Bessard, Anne Claire ;

Lamy, Regine ;

Levy, Christelle ;

Lortholary, Alain ;

Mailliez, Audrey .

BREAST CANCER RESEARCH AND TREATMENT, 2024, 204 (02) :237-248

[43] Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY [J].

Judith Balmaña ;

Peter A. Fasching ;

Fergus J. Couch ;

Suzette Delaloge ;

Intidhar Labidi-Galy ;

Joyce O’Shaughnessy ;

Yeon Hee Park ;

Andrea F. Eisen ;

Benoit You ;

Hughes Bourgeois ;

Anthony Gonçalves ;

Zoe Kemp ;

Angela Swampillai ;

Tomasz Jankowski ;

Joo Hyuk Sohn ;

Elena Poddubskaya ;

Guzel Mukhametshina ;

Sercan Aksoy ;

Constanta V. Timcheva ;

Tjoung-Won Park-Simon ;

Antonio Antón-Torres ;

Ellie John ;

Katherine Baria ;

Isabel Gibson ;

Karen A. Gelmon .

Breast Cancer Research and Treatment, 2024, 204 :237-248

[44] Cisplatin versus doxorubicin/cyclophosphamide as neoadjuvant treatment in germline BRCA mutation carriers (BRCA carriers) with HER2-negative breast cancer: Results from the INFORM trial (TBCRC 031) [J].

Tung, Nadine ;

Arun, Banu ;

Hofstatter, Erin ;

Hacker, Michele R. ;

Toppmeyer, Deborah L. ;

Isakoff, Steven J. ;

Borges, Virginia ;

Legare, Robert D. ;

Isaacs, Claudine ;

Wolff, Antonio C. ;

Marcom, Paul K. ;

Mayer, Erica L. ;

Lange, Paulina B. ;

Goss, Andrew J. ;

Krop, Ian E. ;

Winer, Eric P. ;

Schnitt, Stuart J. ;

Garber, Judy E. .

CANCER RESEARCH, 2020, 80 (04)

[45] Trastuzumab (T) Treatment Outcomes According to Concomitant Chemotherapy Regimen: Overall Survival (OS) of HER2+Metastatic Breast Cancer (MBC) Patients [J].

Pearson, Sallie-Anne ;

Srasuebkul, Preeyaporn ;

Harris, Carole ;

Ward, Robyn ;

Dobbins, Timothy .

PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2010, 19 :S187-S187

[46] Overall survival (OS) results from the phase III TROPiCS-02 study of sacituzumab govitecan (SG) vs treatment of physician's choice (TPC) in patients (pts) with HR+/HER2-metastatic breast cancer (mBC) [J].

Rugo, H. S. ;

Bardia, A. ;

Marme, F. ;

Cortes, J. ;

Schmid, P. ;

Loirat, D. ;

Tredan, O. ;

Ciruelos, E. M. ;

Dalenc, F. ;

Gomez Pardo, P. ;

Jhaveri, K. ;

Delaney, R. J. ;

Valdez, T. ;

Wang, H. ;

Verret, W. ;

Tolaney, S. M. .

ANNALS OF ONCOLOGY, 2022, 33 (07) :S1386-S1386

[47] Efficacy and safety of talazoparib (TALA) or physician's choice of therapy (PCT) in United States patients (pts) with HER2-germline BRCA1/2-mutated (gBRCAm) locally advanced/metastatic breast cancer (LA/MBC) in the EMBRACA study. [J].

Diab, Sami ;

Rugo, Hope S. ;

Mina, Lida A. ;

Puhalla, Shannon ;

Mahtani, Reshma L. ;

Henry, Norah Lynn ;

Denduluri, Neelima ;

Yardley, Denise A. ;

Wang, Yao ;

Arruda, Lillian Shahied ;

Tudor, Iulia Cristina ;

Gauthier, Eric Roland ;

Czibere, Akos Gabor ;

Litton, Jennifer Keating ;

Hurvitz, Sara A. .

JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)

[48] Trastuzumab emtansine improves overall survival versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer: Final overall survival results from the phase 3 TH3RESA study [J].

Wildiers, H. ;

Kim, S-B ;

Gonzalez-Martin, A. ;

LoRusso, P. M. ;

Ferrero, J-M ;

Yu, R. ;

Smitt, M. ;

Krop, I. .

CANCER RESEARCH, 2016, 76

[49] Patient-reported outcomes (PRO) in patients (pts) with advanced breast cancer and a germline BRCA1/2 mutation (gBRCAm) receiving talazoparib (TALA) vs physician's choice chemotherapy treatment (PCT): A focus on the EMBRACA triple negative (TNBC) subpopulation [J].

Rugo, H. S. ;

Quek, R. ;

Ettl, J. ;

Hurvitz, S. A. ;

Bhattacharyya, H. ;

Hannah, A. L. ;

Litton, J. K. .

ANNALS OF ONCOLOGY, 2018, 29

[50] Trastuzumab deruxtecan (T-DXd) versus treatment of physician's choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Updated survival results of the randomized, phase III DESTINY-Breast04 study [J].

Modi, S. ;

Jacot, W. ;

Iwata, H. ;

Park, Y. H. ;

Vidal Losada, M. J. ;

Li, W. ;

Tsurutani, J. ;

Zaman, K. ;

Ueno, N. T. ;

Prat, A. ;

Papazisis, K. ;

Rugo, H. S. ;

Harbeck, N. ;

Im, S-A. ;

De Laurentiis, M. ;

Orbegoso, C. M. A. ;

Yung, L. ;

Cheng, F-C. ;

Cheng, Y. ;

Cameron, D. A. .

ANNALS OF ONCOLOGY, 2023, 34 :S334-S335

← 1 2 3 4 5 →